The world's biggest healthcare company said it experienced surging demand for its GLP-1 Zepbound weight loss drug.
Eli Lilly raised its 2024 revenue guidance, suggesting that the supply shortage of its weight loss drug may soon ease.
The results showed soaring demand for its GLP-1 weight loss drug Zepbound, and the revenue guidance increase suggests that ongoing supply shortages of the drug may soon ease.
"We have approximately 67% access in the commercial segment," Eli Lilly CFO Anat Ashkenazi said on the company's earnings call.
Eli Lilly is looking to expand its indications of Zepbound so it can treat more health problems, including sleep apnea.
Persons:
Eli Lilly, —, Zepbound, David Ricks, Eli Lilly's, Anat Ashkenazi, Ashkenazi, LLY, JPMorgan, JPMorgan isn't
Organizations:
Service, JPMorgan
Locations:
America